Medical company makes $1m breakthrough in US market

YORK regenerative medical company Tissue Regenix has cracked the US market, reaching the $1m sales mark for its wound care product.

DermaPure was commercialised in the US and the company has now reached the million-dollar milestone for the product.

It is now available to almost 65% of Medicare beneficiaries, across 31 states.

The product is aimed at the treatment of chronic wounds associated with diabetes, and can also treat those as a result of pressure ulcers or frostbite.

Approximately 10% of the American population suffer from Type I or Type 2 diabetes, according to Tissue Regenix, making it a lucrative market for DermaPure.

Greg Bila, president of Tissue Regenix Woundcare, Inc. commented, “Since launch in 2014, the uptake of DermaPure® within a competitive marketplace has been highly encouraging and we are thrilled to announce the first $1m of sales.

“Unlike cell based products, DermaPure® signals the body to redirect the patient’s own cells to the affected area, allowing the body to regenerate healthy tissue.”

Tissue Regenix, a University of Leeds spin-out, undertook a £19m fundraising effort last February to fuel expansion, and moved to a new EU manufacturing site in Swillington, Leeds.

The company has also announced that the chief executive of Consort Medical is to join the board as a non-executive director.

Jonathan Glenn with immediate effect. Read more here .